Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 10-Q

 


 

(MARK ONE)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2004

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                     to                     

 

Commission file number: 1-14200

 


 

CAREMARK RX, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware   63-1151076

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

211 Commerce Street, Suite 800

Nashville, Tennessee 37201

(Address and zip code of principal executive offices)

 

(615) 743-6600

(Registrant’s telephone number, including area code)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    Yes  x    No  ¨

 

As of July 31, 2004, the registrant had 465,991,969 shares (including 6,179,927 shares held in trust to be utilized in employee benefit plans) of common stock, par value $.001 per share, issued and outstanding.

 



Table of Contents

FORWARD LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS

 

In passing the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), 15 U.S.C.A. Sections 77z-2 and 78u-5 (Supp. 1996), Congress encouraged public companies to make “forward looking statements” by creating a safe harbor to protect companies from securities law liability in connection with forward-looking statements. Caremark Rx, Inc. (“Caremark Rx”) intends to qualify both its written and oral forward-looking statements for protection under the Reform Act and any other similar safe harbor provisions. Unless the context indicates otherwise, the words “Company,” “we,” “our,” and “us,” whenever used in this Quarterly Report on Form 10-Q, refer collectively to Caremark Rx and its wholly-owned subsidiaries.

 

“Forward-looking statements” are defined by the Reform Act. Generally, forward-looking statements include expressed expectations of future events and the assumptions on which these expressed expectations are based. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events, and they are subject to numerous known and unknown risks and uncertainties which could cause actual events or results to differ materially from those projected. Due to such risks and uncertainties, the investment community is urged not to place undue reliance on our written or oral forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

 

Forward-looking statements are contained in this document, primarily under the caption: “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” referred to as MD&A, and in the “Notes to Condensed Consolidated Financial Statements” appearing under Item 1. Moreover, through our senior management, we may from time to time make forward-looking statements about matters described herein or about other matters concerning us.

 

There are several factors which could adversely affect our operations and financial results, including, but not limited to, the following:

 

  Risks relating to identification of, and competition for, growth and expansion opportunities;

 

  Risks relating to declining reimbursement levels for, or increases in the costs of, products dispensed;

 

  Risks relating to exposure to liabilities in excess of our insurance;

 

  Risks relating to compliance with, or changes in, government regulation and legislation, including, but not limited to, pharmacy licensing requirements, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and healthcare reform legislation;

 

  Risks relating to adverse developments in any investigation related to the pharmaceutical industry that may be conducted by governmental authorities;

 

  Risks relating to adverse resolution of existing or future lawsuits;

 

  Risks relating to successful integration of AdvancePCS;

 

  Risks relating to our liquidity and capital requirements; and

 

  Risks relating to our ability to successfully terminate leases and other contractual agreements related to our discontinued operations and the outcome of various legal disputes surrounding the closure or sale of our Physician Practice Management (“PPM”) business.

 

More detailed discussions of certain of these risk factors can be found under the captions: “Business,” “Legal Proceedings” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in the “Notes to Consolidated Financial Statements” contained in our Annual Report on Form 10-K for the year ended December 31, 2003, which was filed with the Securities and Exchange Commission on March 9, 2004.

 

i


Table of Contents

CAREMARK RX, INC. AND SUBSIDIARIES

 

QUARTERLY REPORT ON FORM 10-Q

 

INDEX

 

          Page

PART I — FINANCIAL INFORMATION     

Item 1.

   Financial Statements     
    

Condensed Consolidated Balance Sheets — June 30, 2004 (Unaudited) and December 31, 2003

   2
    

Condensed Consolidated Statements of Income (Unaudited) — Three Months and Six Months Ended June 30, 2004 and 2003

   3
    

Condensed Consolidated Statements of Cash Flows (Unaudited) — Six Months Ended June 30, 2004 and 2003

   4
     Notes to Condensed Consolidated Financial Statements (Unaudited)    5

Item 2.

   Management’s Discussion and Analysis of Financial Condition and Results of Operations    17

Item 3.

   Quantitative and Qualitative Disclosures About Market Risk    26

Item 4.

   Controls and Procedures    26
PART II — OTHER INFORMATION     

Item 1.

   Legal Proceedings    27

Item 2.

   Unregistered Sales of Equity Securities and Use of Proceeds    27

Item 4.

   Submission of Matters to a Vote of Security Holders    28

Item 6.

   Exhibits and Reports on Form 8-K    28

Signatures

   29

 

1


Table of Contents

CAREMARK RX, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

 

    

June 30,

2004


   

December 31,

2003


 
    
     (Unaudited)        
ASSETS                 

Current assets:

                

Cash and cash equivalents

   $ 873,236     $ 815,328  

Accounts receivable, less allowance for doubtful accounts of $46,508 in 2004 and $24,746 in 2003

     2,052,715       669,680  

Inventories

     270,161       204,939  

Deferred tax asset, net

     383,508       240,978  

Prepaid expenses and other current assets

     25,374       15,752  
    


 


Total current assets

     3,604,994       1,946,677  

Property and equipment, net of accumulated depreciation of $200,912 in 2004 and $164,232 in 2003

     294,202       159,769  

Goodwill

     6,880,906       49,171  

Intangible assets, net of accumulated amortization of $25,548 in 2004 and $18,928 in 2003

     943,016       9,273  

Deferred tax asset, net

     —         227,426  

Other non-current assets

     58,524       81,312  
    


 


Total assets

   $ 11,781,642     $ 2,473,628  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY                 

Current liabilities:

                

Accounts payable

   $ 560,641     $ 385,362  

Claims and discounts payable

     2,456,880       509,713  

Other accrued expenses and liabilities

     287,254       158,666  

Income taxes payable

     6,640       7,820  

Current portion of long-term debt

     4,000       2,500  
    


 


Total current liabilities

     3,315,415       1,064,061  

Long-term debt, net of current portion

     596,610       693,125  

Deferred tax liability

     65,222       —    

Other long-term liabilities

     264,690       75,804  
    


 


Total liabilities

     4,241,937       1,832,990  

Commitments and contingencies

                

Stockholders’ equity:

                

Common stock, $.001 par value per share; 700,000 shares authorized;
issued — 471,002 shares in 2004 and 268,578 shares in 2003

     471       269  

Additional paid-in capital

     8,507,866       1,762,477  

Unearned stock-based compensation

     (37,391 )     —    

Treasury stock — 2,905 shares in 2004 and 1,855 shares in 2003

     (62,391 )     (28,782 )

Shares held in trust — 6,205 shares in 2004 and 6,263 shares in 2003

     (100,034 )     (101,103 )

Accumulated deficit

     (757,826 )     (981,233 )

Accumulated other comprehensive loss

     (10,990 )     (10,990 )
    


 


Total stockholders’ equity

     7,539,705       640,638  
    


 


Total liabilities and stockholders’ equity

   $ 11,781,642     $ 2,473,628  
    


 


The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of these

balance sheets.

 

2


Table of Contents

CAREMARK RX, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per share amounts)

 

     Three Months Ended
June 30,


  

Six Months Ended

June 30,


     2004

   2003

   2004

   2003

Net revenue (1)

   $ 7,304,442    $ 2,204,039    $ 10,330,385    $ 4,367,835

Operating expenses:

                           

Cost of revenues (1)(2)

     6,894,591      2,019,399      9,689,402      4,011,100

Selling, general and administrative expenses

     119,945      48,785      175,856      94,888

Depreciation

     24,474      10,740      37,263      20,599

Amortization of intangible assets

     12,300      18      13,359      35

Interest expense, net

     8,578      10,875      18,408      21,969

Stock option expense

     8,266      —        9,085      —  

Integration and other related expenses

     5,028      —        15,438      —  
    

  

  

  

Income before provision for income taxes

     231,260      114,222      371,574      219,244

Provision for income taxes

     92,041      45,688      148,167      87,697
    

  

  

  

Net income

   $ 139,219    $ 68,534    $ 223,407    $ 131,547
    

  

  

  

Average number of common shares outstanding - basic

     459,817      256,391      368,785      255,864

Common stock equivalents - stock options and warrants

     11,110      7,215      9,635      6,832
    

  

  

  

Average number of common shares outstanding - diluted

     470,927      263,606      378,420      262,696
    

  

  

  

Net income per common share - basic

   $ 0.30    $ 0.27    $ 0.61    $ 0.51
    

  

  

  

Net income per common share - diluted

   $ 0.30    $ 0.26    $ 0.59    $ 0.50
    

  

  

  


(1) Includes approximately $1.3 billion and $304 million of retail copayments for the three months ended June 30, 2004 and 2003, and approximately $1.8 billion and $615 million of retail copayments for the six months ended June 30, 2004 and 2003, respectively.
(2) Excludes depreciation expense, which is presented separately.

 

The accompanying Notes to Condensed Consolidated Financial Statements are an integral part of

these statements.

 

3


Table of Contents

CAREMARK RX, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

    

Six Months Ended

June 30,


 
     2004

    2003

 

Cash flows from continuing operations:

                

Net income

   $ 223,407     $ 131,547  

Adjustments to reconcile net income to net cash provided by continuing operations:

                

Deferred income taxes

     101,252       78,058  

Depreciation and amortization

     50,622       20,634  

Provision for doubtful accounts

     8,318       6,758  

Non-cash interest expense

     1,645       1,804  

Writeoff of deferred financing costs

     2,206       —    

Stock option expense

     9,085       —    

Other non-cash expenses

     249       541  

Changes in operating assets and liabilities, net of effects of acquisitions and disposals of businesses

     305,112       28,049  
    


 


Net cash provided by continuing operations

     701,896       267,391  

Cash flows from investing activities:

                

Capital expenditures, net

     (31,151 )     (26,589 )

Acquisitions of businesses, net of cash acquired

     (391,021 )     (319 )

Partial liquidation of cost-method investment

     10,382       —    
    


 


Net cash used in investing activities

     (411,790 )     (26,908 )

Cash flows from financing activities:

                

Repayments under credit facilities

     (246,625 )     (1,250 )

Borrowing under new term loan

     150,000       —    

Principal payment under AdvancePCS Senior Notes Tender Offer

     (206,810 )     —    

Net proceeds from exercise of stock options and retirement of warrants

     113,691       39,214  

Purchase of treasury stock

     (33,609 )     (6,111 )

Deferred financing costs

     (3,857 )     (100 )

Securities issuance costs

     (2,729 )     —    
    


 


Net cash provided by (used in) financing activities

     (229,939 )     31,753  

Cash used in discontinued operations

     (2,259 )     (53,262 )
    


 


Net increase in cash and cash equivalents

     57,908       218,974  

Cash and cash equivalents — beginning of period

     815,328       306,804  
    


 


Cash and cash equivalents — end of period

   $ 873,236     $ 525,778  
    


 


Non-cash investing activities related to the AdvancePCS Acquisition:

                

Fair value of non-cash net assets acquired (based on the Company’s preliminary purchase price allocation)

   $ 6,913,941          
    


       

Issuance of approximately 191 million shares of common stock

   $ 6,227,720          

Issuance of replacement stock options for the purchase of approximately 14 million shares of common stock, net of approximately $49.9 million allocated to unearned compensation

     271,909          

Issuance of replacement warrants for the purchase of approximately 902,000 shares of common stock

     15,000          
    


       
     $ 6,514,629